Department of Breast Surgery, The First Affiliated Hospital, Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Department of Neonatal Intensive Care Unit, The Second Affiliated Hospital, Anhui Medical University, Hefei, China.
Aging (Albany NY). 2024 Feb 14;16(4):3531-3553. doi: 10.18632/aging.205544.
Despite the advent of precision therapy for breast cancer (BRCA) treatment, some individuals are still unable to benefit from it and have poor survival prospects as a result of the disease's high heterogeneity. Cell senescence plays a crucial role in the tumorigenesis, progression, and immune regulation of cancer and has a major impact on the tumor microenvironment. To find new treatment strategies, we aimed to investigate the potential significance of cell senescence in BRCA prognosis and immunotherapy. We created a 9-gene senescence-related signature. We evaluated the predictive power and the role of signatures in the immune microenvironment and infiltration. tests were used to validate the expression and function of the distinctive critical gene ACTC1. Our risk signature allows BRCA patients to receive a Predictive Risk Signature (PRS), which may be used to further categorize a patient's response to immunotherapy. Compared to conventional clinicopathological characteristics, PRS showed strong predictive efficacy and precise survival prediction. Moreover, PRS subgroups were examined for altered pathways, mutational patterns, and possibly useful medicines. Our research offers suggestions for incorporating senescence-based molecular classification into risk assessment and ICI therapy decision-making.
尽管出现了针对乳腺癌（BRCA）治疗的精准疗法，但由于该疾病的高度异质性，一些人仍然无法从中受益，生存前景较差。细胞衰老在癌症的发生、进展和免疫调节中起着至关重要的作用，并对肿瘤微环境产生重大影响。为了寻找新的治疗策略，我们旨在研究细胞衰老在 BRCA 预后和免疫治疗中的潜在意义。我们创建了一个 9 个基因衰老相关的特征。我们评估了特征在免疫微环境和浸润中的预测能力和作用。使用 检验来验证独特关键基因 ACTC1 的表达和功能。我们的风险特征允许 BRCA 患者接受预测风险特征（PRS），这可能用于进一步对患者对免疫治疗的反应进行分类。与传统的临床病理特征相比，PRS 显示出强大的预测效力和精确的生存预测。此外，还检查了 PRS 亚组的改变途径、突变模式和可能有用的药物。我们的研究为将基于衰老的分子分类纳入风险评估和 ICI 治疗决策提供了建议。
